Count the development pipeline
count_pipelineRead-onlyIdempotent
How many drug and therapy programmes there are, grouped by stage, modality, target, hallmark, indication, the developer's country or the developer, with each group's count at each stage. Takes list_assets' filters: by=target with indication=obesity counts the targets of obesity programmes. An account whose plan includes drug and therapy programmes reads every record in full; any other caller reads the outline AgingResearch.News shows on its asset pages.
Input Schema
TableJSON Schema
| Name | Required | Description | Default |
|---|---|---|---|
| q | No | Letters and digits in any of the asset's names or code names (`UBX1325` matches UBX-1325). | |
| by | No | What to group by. | stage |
| limit | No | Results per page, 1 to 25. | |
| stage | No | Stage: with `indication`, the stage for that indication; otherwise the asset's furthest stage. | |
| target | No | A target: a gene symbol or key (`GLP1R`, `bcl2l1`) or a process key (`mtor`, `cellular-senescence`). | |
| country | No | The developer's country, ISO 3166 alpha-2 (`US`, `GB`, `CH`). | |
| hallmark | No | A hallmark of aging the asset acts on. | |
| modality | No | The kind of therapy (see `modality`). | |
| mechanism | No | Words that must all appear in the asset's mechanism line (case-insensitive). | |
| indication | No | A disease, by name or entity key (`idiopathic pulmonary fibrosis`, `alzheimer-disease`). | |
| organisation | No | An organisation key: the assets it develops, partners on or licensed out. |